PtdIns-4,5-P2 as a potential therapeutic target for pathologic angiogenesis.
A variety of diseases arise, at least in part, when the events controlling the formation and stability of blood vessels are deregulated. For instance, the growth and survival of solid tumors are tightly linked to their ability to undergo vascularization. Similarly, pathologic angiogenesis of the retina or choroid underscores blinding diseases that afflict a substantial percentage of the world's population. Therefore, it is of great interest to develop antiangiogenic drugs that will relieve the burden of vascular diseases such as cancer, age-related macular degeneration and proliferative diabetic retinopathy. In this article, the authors highlight their recent discovery that PtdIns-4,5-P2)can regulate vessel stability. This finding identifies PtdIns-4,5-P2 as a novel target for angiogenesis therapies.
Im
Eunok
E
Schepens Eye Research Institute, Harvard Medical School, 20 Staniford Street, Boston, MA 02114, USA.
Kazlauskas
Andrius
A
D006801:Humans; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000378:metabolism*; D019269:Phosphatidylinositol 4,5-Diphosphate / Q000037:antagonists & inhibitors* / Q000378:metabolism*
D019269:Phosphatidylinositol 4,5-Diphosphate